Desidustat is an antianaemic drug candidate under investigation for the treatment of anemia of chronic kidney disease. It acts as an inhibitor of HIF hydroxylase. Reference: Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation. Eur J Pharmacol. 2019 Jan 15;843:113-120.

PT2399 is a novel, potent, and orally bioavailable small molecule inhibitor of HIF-2 which binds to HIF-2α PAS B domain with an IC50 of 6 nM, exhibiting potent antitumor activity in vivo.. It selectively disrupts the heterodimerization of HIF-2α with HIF-1β. Preclinical and clinical data indicate that PT2399 is effective in blocking cancer cell growth, […]